24 new BTP derivatives were developed as STAT3 inhibitors for anticancer agents. 15 exhibited potent antitumor activity in vitro and in vivo. 15 selectively inhibited STAT3 activity without affecting the upstream kinases. 15 exhibited less toxicity than Doxorubicin in vivo. Docking study was conducted to further understand the SAR.